ETA/EUGOGO Guidelines
Publications
Our multicentric network of Joint TECs around Europe published a huge number of papers in scientific journals. Papers on assessment and treatment recommendations, observational studies as well as RCTs –all of them reflecting the scientific power of a multidisciplinary approach.
Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement.
Orphanet Journal of Rare Diseases 2017; 12:72 DOI 10.1186/s13023-017-0625-1 P. Perros, L. Hegedüs, L. Bartalena, C. Marcocci, GJ Kahaly, L Baldeschi, M. Salvi, JH Lazarus, A. Eckstein, S. Pitz, K. Boboridis, P. Anagnostis, G. Ayvaz, A. Boschi, TH Brix, N. Curro, O. Konuk, M. Marino, AL Mitchell, B. Stankovic, FB Törüner, G .von Arx, M. Zarkovic and WM Wiersinga.
Future Research in Graves’ Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement.
Thyroid 2015 Nov;25(11):1181-4. doi: 10.1089/thy.2015.0222. Epub 2015 Oct 14. Perros P, Dayan CM, Dickinson AJ, Ezra DG, Hickey JL, Hintschisch C, Kahaly GJ, Lazarus JH, Ludgate M, Bartès B, MacEwen CJ, Mitchell AL, Morris D, O’Connor N, Pearce SH, Rose GE, Salvi M, Wiersinga WM, Williamson
PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group On Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.
Br J Ophthalmol. 2015 Nov;99(11):1531-5. doi: 10.1136/bjophthalmol-2015-306733. Epub 2015 May 7. Perros P, Žarković M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, Boschi A, Bournaud C, Brix TH, Covelli D, Ćirić S, Daumerie C, Eckstein A, Fichter N, Führer D, Hegedüs L, Kahaly GJ, Konuk O, Lareida J, Lazarus J, Leo M, Mathiopoulou L, Menconi F, Morris D, Okosieme O, Orgiazzi J, Pitz S, Salvi M, Vardanian-Vartin C, Wiersinga W, Bernard M, Clarke L, Currò N, Dayan C, Dickinson J, Knežević M, Lane C, Marcocci C, Marinò M, Möller L, Nardi M, Neoh C, Pearce S, von Arx G, Törüner FB
Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy.
J Clin Endocrinol Metab. 2012 Dec;97(12):4454-63. doi: 10.1210/jc.2012-2389. Epub 2012 Oct 4. Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G; European Group on Graves’ Orbitopathy.
Fatal and non-fatal adverse events of glucocorticoid therapy for Graves’ orbitopathy: a questionnaire survey among members of the European Thyroid Association.
Eur J Endocrinol. 2012 Feb;166(2):247-53. doi: 10.1530/EJE-11-0779. Epub 2011 Nov 4. Marcocci C, Watt T, Altea MA, Rasmussen AK, Feldt-Rasmussen U, Orgiazzi J, Bartalena L; European Group of Graves’ Orbitopathy.
Selenium and the course of mild Graves’ orbitopathy.
N Engl J Med. 2011 May 19;364(20):1920-31. doi: 10.1056/NEJMoa1012985. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W; European Group on Graves’ Orbitopathy.